Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)

US8956607B2 · kind B2 · utility

Assignee

• Biotest AG · DE

Inventors

• Frank Osterroth · Dietzenbach, DE
• Christoph Uherek · Seligenstadt, DE
• Christoph Bruecher · Eschborn, DE
• Peter Röttgen · Ladenburg, DE
• Benjamin Daelken · Frankfurt am Main, DE
• André Engling · Frankfurt, DE
• Chantal Zuber · Frankfurt am Main, DE
• Niklas Czeloth · Dreieich, DE

Key dates

• Filing date: Nov 30, 2010
• Grant date: Feb 17, 2015
• Expiry date: Nov 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor α(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.